Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study
Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study in type 1 diabetes CARY, N.C. and NEW YORK, March 24, 2026 /PRNewswire/ -- Continuity Biosciences and Breakthrough T1D, the leading global type 1...